Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.

Daniela A FerraroHelena I Garcia SchülerUrs J MuehlematterDaniel EberliJulian MüllerAlexander MüllerRoger GablingerHelmut KranzbühlerAurelius OmlinPhilipp A KaufmannThomas HermannsIrene Andrea Burger

Published in: European journal of nuclear medicine and molecular imaging (2019)

Information from 68Ga-PSMA-11 PET staging has the potential to change the management in more than a fourth of the patients who underwent PET staging for their intermediate to high-risk prostate cancer. Whether these more personalized 68Ga-PSMA-11 PET-based treatment decisions will improve patient outcome needs further investigation.

Keyphrases

pet ct
prostate cancer
positron emission tomography
end stage renal disease
radical prostatectomy
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
lymph node
healthcare
computed tomography
patient reported outcomes
health information
combination therapy
replacement therapy